Ticker Launch
Sign inTry it free

SPAC · Merger completed

Longevity Acquisition Corp

Business combination with 4D pharma plc

Longevity Acquisition Corp is a blank-check company (SPAC) that raised $40M in its initial public offering on Aug 29, 2018, listing on Nasdaq Capital Market. It completed its business combination with 4D pharma plc on Mar 22, 2021; the combined company is 4D pharma plc (ADSs) (LBPS). Ellenoff Grossman & Schole advised the SPAC and Loeb & Loeb advised the underwriters on the IPO.

4D pharma plc is a clinical-stage biotechnology company developing Live Biotherapeutic Products, orally delivered single bacterial strains from the healthy human gut. Programs include MRx0518 in solid tumors, MRx-4DP0004 in asthma, and Blautix for irritable bowel syndrome.

Status
Merger completed
IPO date
Aug 29, 2018
IPO size
$40M
IPO exchange
Nasdaq Capital Market
Target
4D pharma plc
Announced
Oct 22, 2020
Closed
Mar 22, 2021
Combined company
4D pharma plc (ADSs) (LBPS)
SPAC counsel (IPO)
Ellenoff Grossman & Schole and Ogier
Underwriters' counsel (IPO)
Loeb & Loeb

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2021